Histopathological evaluation of recurrent hepatitis C after liver transplantation: A review

World Journal of Gastroenterology

Volumn 20, Issue 11, 2014, Pages 2810-2824

  Vasuri, Francesco ^a   Malvi, Deborah ^a   Gruppioni, Elisa ^a   Grigioni, Walter F ^a   D'Errico Grigioni, Antonia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatitis C virus; Histopathology; Immunohistochemistry; Orthotopic liver transplantation; Polymerase chain reaction; Recurrent hepatitis C

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CLAUDIN 1; COMPLEMENT COMPONENT C4D; CYTOKERATIN 19; FAS LIGAND; INTERLEUKIN 28B; MINICHROMOSOME MAINTENANCE PROTEIN 2; MYXOVIRUS RESISTANCE PROTEIN A; VIMENTIN; VIRUS RNA;

AGE; ALLOGRAFT; ARTICLE; CELL ACTIVATION; CHOLESTASIS; CHOLESTATIC HEPATITIS; COUNCILMAN BODY; DIFFERENTIAL DIAGNOSIS; DNA POLYMORPHISM; GENETIC VARIABILITY; GRANULOMA; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KUPFFER CELL; LIVER BIOPSY; LIVER CELL; LIVER TRANSPLANTATION; NONHUMAN; ORGAN DONOR; PLASMA CELL; PORTAL VEIN; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEATOSIS; STELLATE CELL; BIOPSY; LIVER; PATHOLOGY; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; VIROLOGY;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; RECURRENCE;

EID: 84896460430     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i11.2810     Document Type: Article

References (136)

1. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012; 26: 531-548 [PMID: 23199510 DOI: 10.1002/lt.23559]
2. Belli LS, Alberti A, Rondinara GF, de Carlis L, Romani F, Ideo G, Belli L. Recurrent HCV hepatitis after liver transplantation. Lancet 1993; 341: 378 [PMID: 7679178]
3. Shiffman ML, Contos MJ, Luketic VA, Sanyal AJ, Purdum PP, Mills AS, Fisher RA, Posner MP. Biochemical and histologic evaluation of recurrent hepatitis C following orthotopic liver transplantation. Transplantation 1994; 57: 526-532 [PMID: 8116036]
4. Greenson JK, Svoboda-Newman SM, Merion RM, Frank TS. Histologic progression of recurrent hepatitis C in liver transplant allografts. Am J Surg Pathol 1996; 20: 731-738 [PMID: 8651353]
5. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820 [PMID: 8596547]
6. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, Zhang D, Gerber MA, Miller CM, Bodenheimer HC. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-976 [PMID: 8621177]
7. Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ, Wiesner RH, Charlton MR, Persing DH. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000; 13: 229-237 [PMID: 10757333]
8. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002; 8: S7-S13 [PMID: 12362292]
9. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687 [PMID: 11870384]
10. Guo L, Orrego M, Rodriguez-Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006; 12: 560-565 [PMID: 16555313]
11. Khettry U, Huang WY, Simpson MA, Pomfret EA, Pomposelli JJ, Lewis WD, Jenkins RL, Gordon FD. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007; 38: 443-452 [PMID: 17188331]
12. Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transpl 2009; 15 Suppl 2: S35-S41 [PMID: 19876940 DOI: 10.1002/lt.21890]
13. Pacholczyk M, Łagiewska B, Lisik W, Tronina O, Wasiak D, Cieciura T, Chmura A. Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience. Ann Transplant 2012; 17: 5-10 [PMID: 23274318]
14. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, Combs C, Fennessy S, Roberts JP, Ascher NL. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-322 [PMID: 1377143]
15. Randhawa PS, Demetris AJ. Hepatitis C virus infection in liver allografts. Pathol Annu 1995; 30 Pt 2: 203-226 [PMID: 8570276]
16. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881 [PMID: 19938138 DOI: 10.1002/lt.21954]
17. Shuhart MC, Bronner MP, Gretch DR, Thomassen LV, Wartelle CF, Tateyama H, Emerson SS, Perkins JD, Carithers RL. Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology 1997; 26: 1646-1652 [PMID: 9398011]
18. Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, García-Herola A, Olaso V, De Juan M, Gobernado M, Mir J, Berenguer J. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256 [PMID: 9862874]
19. Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, Futagawa S. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surg Today 2003; 33: 421-425 [PMID: 12768367]
20. Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol 2013; 35: 101-110 [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5]
21. Mells G, Neuberger J. Protocol liver allograft biopsies. Transplantation 2008; 85: 1686-1692 [PMID: 18580457 DOI: 10.1097/TP.0b013e318176b1fd]
22. Vasuri F, Morelli MC, Gruppioni E, Fiorentino M, Ercolani G, Cescon M, Pinna AD, Grigioni WF, D'Errico-Grigioni A. The meaning of tissue and serum HCV RNA quantitation in hepatitis C recurrence after liver transplantation: a retrospective study. Dig Liver Dis 2013; 45: 505-509 [PMID: 23317815 DOI: 10.1016/j.dld.2012.11.015]
23. D'Errico-Grigioni A, Fiorentino M, Vasuri F, Gruppioni E, Fabbrizio B, Zucchini N, Ballardini G, Morelli C, Pinna AD, Grigioni WF. Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation. Liver Transpl 2008; 14: 313-320 [PMID: 18306349 DOI: 10.1002/lt.21375]
24. Saraf N, Fiel MI, Deboccardo G, Emre S, Schiano TD. Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl 2007; 13: 913-917 [PMID: 17539015]
25. Park YN, Boros P, Zhang DY, Sheiner P, Kim-Schluger L, Thung SN. Serum hepatitis C virus RNA levels and histologic findings in liver allografts with early recurrent hepatitis C. Arch Pathol Lab Med 2000; 124: 1623-1627 [PMID: 11079013]
26. Demetris AJ, Eghtesad B, Marcos A, Ruppert K, Nalesnik MA, Randhawa P, Wu T, Krasinskas A, Fontes P, Cacciarelli T, Shakil AO, Murase N, Fung JJ, Starzl TE. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004; 28: 658-669 [PMID: 15105656]
27. Crespo J, Rivero M, Mayorga M, Fabrega E, Casafont F, Gomez-Fleitas M, Pons-Romero F. Involvement of the fas system in hepatitis C virus recurrence after liver transplantation. Liver Transpl 2000; 6: 562-569 [PMID: 10980054]
28. Di Martino V, Brenot C, Samuel D, Saurini F, Paradis V, Reynés M, Bismuth H, Féray C. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C. Transplantation 2000; 70: 1390-1396 [PMID: 11087158]
29. Lim EJ, Chin R, Angus PW, Torresi J. Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants. World J Gastroenterol 2012; 18: 2172-2179 [PMID: 22611309 DOI: 10.3748/wjg.v18.i18.2172]
30. Saxena R, Crawford JM, Navarro VJ, Friedman AL, Robert ME. Utilization of acidophil bodies in the diagnosis of recurrent hepatitis C infection after orthotopic liver transplantation. Mod Pathol 2002; 15: 897-903 [PMID: 12218206]
31. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157 [PMID: 1988336]
32. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228-1235 [PMID: 21031537 DOI: 10.1002/lt.22175]
33. Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrell LD. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 1998; 4: 304-310 [PMID: 9649645]
34. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13: 219-226 [PMID: 17205558]
35. Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013; 19: 78-88 [PMID: 23081888]
36. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40: 368-374 [PMID: 15123347]
37. Doughty AL, Painter DM, McCaughan GW. Nonspecificity of monoclonal antibody Tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis. Liver Transpl Surg 1999; 5: 40-45 [PMID: 9873091]
38. Deshpande V, Burd E, Aardema KL, Ma CK, Moonka DK, Brown KA, Abouljoud MS, Nakhleh RE. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl 2001; 7: 118-124 [PMID: 11172395]
39. Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14: 861-871 [PMID: 18508382 DOI: 10.1002/lt.21447]
40. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006; 12: 827-830 [PMID: 16628699]
41. Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, Morelli MC, Tamè MR, Piscaglia F, Biselli M, Sama C, Mazzella G, Pinna AD, Grazi G, Bernardi M, Andreone P. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007; 56: 237-242 [PMID: 16798778]
42. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-217 [PMID: 21145865 DOI: 10.1016/j.jhep.2010.11.012]
43. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-1139. e1 [PMID: 22285805 DOI: 10.1053/j.gastro.2012.01.030]
44. Ward SC, Schiano TD, Thung SN, Fiel MI. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009; 15: 1826-1833 [PMID: 19938116 DOI: 10.1002/lt.21949]
45. Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: Variant of rejection or autoimmune hepatitis? Liver Transpl 2008; 14: 750-755 [PMID: 18508366 DOI: 10.1002/lt.21518]
46. Bárcena R, Sanromán AL, Del Campo S, García M, Moreno A, De Vicente E, Candela A. Posttransplant liver granulomatosis associated with hepatitis C? Transplantation 1998; 65: 1494-1495 [PMID: 9645809]
47. Ferrell LD, Lee R, Brixko C, Bass NM, Lake JR, Roberts JP, Ascher N, Rabkin J. Hepatic granulomas following liver transplantation. Clinicopathologic features in 42 patients. Transplantation 1995; 60: 926-933 [PMID: 7491695]
48. Vakiani E, Hunt KK, Mazziotta RM, Emond JC, Brown RS, Lefkowitch JH, Bhagat G. Hepatitis C-associated granulomas after liver transplantation: morphologic spectrum and clinical implications. Am J Clin Pathol 2007; 127: 128-134 [PMID: 17145627]
49. Fiel MI, Shukla D, Saraf N, Xu R, Schiano TD. Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation. Transpl Infect Dis 2008; 10: 184-189 [PMID: 17916116]
50. Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, Terrault NA. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011; 17: 1380-1386 [PMID: 21770018 DOI: 10.1002/lt.22389]
51. Subramanian V, Seetharam AB, Vachharajani N, Tiriveedhi V, Angaswamy N, Ramachandran S, Crippin JS, Shenoy S, Chapman WC, Mohanakumar T, Anderson CD. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011; 92: 1259-1268 [PMID: 22011763 DOI: 10.1097/TP.0b013e318235a1ab]
52. Meriden Z, Forde KA, Pasha TL, Hui JJ, Reddy KR, Furth EE, Wells RG. Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8: 289-296, 296. e1-8 [PMID: 19913638 DOI: 10.1016/j.cgh.2009.10.034]
53. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, Corless CL. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178-1182 [PMID: 9603164]
54. Moreira RK, Salomao M, Verna EC, Brown RS, Lefkowitch JH. The Hepatitis Aggressiveness Score (HAS): a novel classification system for post-liver transplantation recurrent hepatitis C. Am J Surg Pathol 2013; 37: 104-113 [PMID: 23060356 DOI: 10.1097/PAS.0b013e31826a92ac]
55. Fujita S, Fujikawa T, Mizuno S, Reed AI, Kim RD, Howard RJ, Firpi RJ, Nelson DR, Hemming AW. Is early recurrence of hepatitis C associated with biliary anastomotic stricture after liver transplantation? Transplantation 2007; 84: 1631-1635 [PMID: 18165775 DOI: 10.1097/01.tp.0000295983.55088.96]
56. Guzman G, Chennuri R, Voros A, Boumendjel R, Locante A, Patel R, Valyi-Nagy T. Nucleometric study of anisonucleosis, diabetes and oxidative damage in liver biopsies of orthotopic liver transplant recipients with chronic hepatitis C virus infection. Pathol Oncol Res 2011; 17: 191-199 [PMID: 20853078 DOI: 10.1007/s12253-010-9296-0]
57. Guido M, Fagiuoli S, Tessari G, Burra P, Leandro G, Boccagni P, Cillo U, Naccarato R, Rugge M. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002; 50: 697-700 [PMID: 11950819]
58. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777 [PMID: 19025933 DOI: 10.1002/lt.21635]
59. McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri M, O'Leary JG, Davis GL, Levy MF, Goldstein RM, Klintmalm GB. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387 [PMID: 21967703 DOI: 10.1111/j.1600-6143.2011.03767.x]
60. Calvaruso V, Dhillon AP, Tsochatzis E, Manousou P, Grillo F, Germani G, Patch D, O'Beirne J, Burroughs AK. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. J Gastroenterol Hepatol 2012; 27: 1227-1232 [PMID: 22432427 DOI: 10.1111/j.1440-1746.2012.07136.x]
61. Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayón M, San Juan F, Landaverde C, Mir J, Berenguer J. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003; 9: 1152-1158 [PMID: 14586875]
62. Berenguer M, Rayón JM, Prieto M, Aguilera V, Nicolás D, Ortiz V, Carrasco D, López-Andujar R, Mir J, Berenguer J. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001; 7: 790-796 [PMID: 11552213]
63. Sebagh M, Rifai K, Féray C, Yilmaz F, Falissard B, Roche B, Bismuth H, Samuel D, Reynès M. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003; 37: 1293-1301 [PMID: 12774007]
64. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, Burgart L, Wiesner R, Kremers W, Rosen C, Charlton MR. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125-1130 [PMID: 11050065]
65. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papatheodoridis GV, Sabin CA, Rolando N, Davies S, Dhillon AP, Griffiths P, Emery V, Patch DW, Davidson BR, Rolles K, Burroughs AK. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386-395 [PMID: 15776454]
66. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, Reed AI, Hemming AW, Liu C, Crawford JM, Nelson DR. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247 [PMID: 15376304]
67. Baiocchi L, Angelico M, Petrolati A, Perrone L, Palmieri G, Battista S, Carbone M, Tariciotti L, Longhi C, Orlando G, Tisone G. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant 2008; 8: 673-678 [PMID: 18294164 DOI: 10.1111/j.1600-6143.2007.02107.x]
68. Ghabril M, Dickson RC, Krishna M, Machicao V, Aranda-Michel J, Bonatti H, Nguyen JH. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence. Liver Transpl 2011; 17: 685-694 [PMID: 21618689 DOI: 10.1002/lt.22250]
69. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836 [PMID: 15519657]
70. Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, Heaton ND, O'Grady JG. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-1929 [PMID: 16780550]
71. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, Pinzello G. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733-740 [PMID: 17370330]
72. Rayhill SC, Wu YM, Katz DA, Voigt MD, Labrecque DR, Kirby PA, Mitros FA, Kalil RS, Miller RA, Stolpen AH, Schmidt WN. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84: 331-339 [PMID: 17700157]
73. Tallón Aguilar L, Molina García D, Barrera Pulido L, Pareja Ciuró F, Suárez Artacho G, Alamo Martínez JM, Bernal Bellido C, García González I, Serrano Díaz-Canedo J, Gómez Bravo MA, Bernardos Rodríguez A. Influence of donor age on survival in liver transplantation due to hepatitis C virus. Transplant Proc 2008; 40: 2968-2970 [PMID: 19010162 DOI: 10.1016/j.transproceed.2008.08.105]
74. Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation 2011; 92: 453-460 [PMID: 21799468 DOI: 10.1097/TP.0b013e3182259282]
75. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS, Contos MJ, Coterell A, Maluf D, Posner MP, Fisher RA. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975-983 [PMID: 17600360]
76. Lionetti R, Tisone G, Palmieri G, Almerighi C, Anselmo A, Tariciotti L, Lenci I, De Luca L, Monaco A, Angelico M. Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression. Dig Liver Dis 2010; 42: 297-303 [PMID: 19818696 DOI: 10.1016/j.dld.2009.08.008]
77. Baiocchi L, Tisone G, Palmieri G, Rapicetta M, Pisani F, Orlando G, Casciani CU, Angelico M. Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation. Liver Transpl Surg 1998; 4: 441-447 [PMID: 9791153]
78. Gordon FD, Pomfret EA, Pomposelli JJ, Lewis WD, Jenkins RL, Khettry U. Severe steatosis as the initial histologic manifestation of recurrent hepatitis C genotype 3. Hum Pathol 2004; 35: 636-638 [PMID: 15138942]
79. Testino G, Sumberaz A, Leone S, Borro P. Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review. Minerva Med 2013; 104: 225-232 [PMID: 23514999]
80. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115 [PMID: 10905593]
81. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000; 6: 44-53 [PMID: 10648577]
82. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293 [PMID: 18756451 DOI: 10.1002/lt.21524]
83. Toniutto P, Fabris C, Avellini C, Minisini R, Bitetto D, Rossi E, Smirne C, Pirisi M. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005; 11: 5944-5950 [PMID: 16273604]
84. Mindikoglu AL, Regev A, Casanova-Romero PY, Bejarano PA, Martinez EJ, Tzakis AG, Schiff ER. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. Transplant Proc 2006; 38: 1440-1444 [PMID: 16797327]
85. Regev A, Molina E, Moura R, Bejarano PA, Khaled A, Ruiz P, Arheart K, Berho M, Drachenberg CB, Mendez P, O'Brien C, Jeffers L, Tzakis A, Schiff ER. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10: 1233-1239 [PMID: 15376303]
86. Petrovic LM, Villamil FG, Vierling JM, Makowka L, Geller SA. Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation. Liver Transpl Surg 1997; 3: 398-406 [PMID: 9346770]
87. Petrovic LM. Early recurrence of hepatitis C virus infection after liver transplantation. Liver Transpl 2006; 12: S32-S37 [PMID: 17051560]
88. Yeh MM, Larson AM, Tung BY, Swanson PE, Upton MP. Endotheliitis in chronic viral hepatitis: a comparison with acute cellular rejection and non-alcoholic steatohepatitis. Am J Surg Pathol 2006; 30: 727-733 [PMID: 16723850]
89. Leung JY, Abraczinskas DR, Bhan AK, Terella AM, Pascual M, Cosimi AB, Chung RT. Recurrent allograft HCV presenting as acute cellular rejection: successful management with interferon and ribavirin alone. Clin Transplant 2003; 17: 275-283 [PMID: 12780680]
90. Cirocco R, Fragulidis GP, Weppler D, Zucker K, Markou M, Zervos XA, Viciana A, Esquinazi V, Nery JR, Reddy KR, Schiff E, Miller J, Tzakis AG. Recurrent hepatitis C infection following orthotopic liver transplantation is predicted by posttransplant serum and hepatic allograft viral titers. Transplant Proc 1997; 29: 2839-2840 [PMID: 9365583]
91. Gottschlich MJ, Aardema KL, Burd EM, Nakhleh RE, Brown KA, Abouljoud MS, Hirst K, Moonka DK. The use of hepatitis C viral RNA levels in liver tissue to distinguish rejection from recurrent hepatitis C. Liver Transpl 2001; 7: 436-441 [PMID: 11349265]
92. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-139 [PMID: 16382465]
93. Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol 2008; 1: 396-402 [PMID: 18787628]
94. Satapathy SK, Sclair S, Fiel MI, Del Rio Martin J, Schiano T. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res 2011; 41: 328-339 [PMID: 21426450 DOI: 10.1111/j.1872-034X.2011.00781.x]
95. Adeyi O, Fischer SE, Guindi M. Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation. J Clin Pathol 2010; 63: 47-74 [PMID: 19847014 DOI: 10.1136/jcp.2009.068254]
96. Teixeira R, Pastacaldi S, Davies S, Dhillon AP, Emery VC, Rolles K, Davidson B, Patch D, Burroughs AK. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70: 1454-1458 [PMID: 11118089]
97. Blight K, Rowland R, Hall PD, Lesniewski RR, Trowbridge R, LaBrooy JT, Gowans EJ. Immunohistochemical detection of the NS4 antigen of hepatitis C virus and its relation to histopathology. Am J Pathol 1993; 143: 1568-1573 [PMID: 8256849]
98. González-Peralta RP, Fang JW, Davis GL, Gish RG, Kohara M, Mondelli MU, Urdea MS, Mizokami M, Lau JY. Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. Dig Dis Sci 1995; 40: 2595-2601 [PMID: 8536518]
99. Vargas V, Krawczynski K, Castells L, Martinez N, Esteban J, Allende H, Esteban R, Guardia J. Recurrent hepatitis C virus infection after liver transplantation: immunohistochemical assessment of the viral antigen. Liver Transpl Surg 1998; 4: 320-327 [PMID: 9649647]
100. Brody RI, Eng S, Melamed J, Mizrachi H, Schneider RJ, Tobias H, Teperman LW, Theise ND. Immunohistochemical detection of hepatitis C antigen by monoclonal antibody TORDJI-22 compared with PCR viral detection. Am J Clin Pathol 1998; 110: 32-37 [PMID: 9661920]
101. Nayak NC, Sathar SA. Immunohistochemical detection of hepatitis C virus antigen in paraffin embedded liver biopsies from patients with chronic liver disease. Acta Histochem 1999; 101: 409-419 [PMID: 10611929]
102. Fenwick F, Bassendine MF, Agarwal K, Bevitt D, Pumeechockchai W, Burt AD, Toms GL. Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation. J Clin Pathol 2006; 59: 174-178 [PMID: 16443734]
103. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, Susca M, Strazzabosco M, Bellusci R, Iemmolo RM, Grazi G, Zauli D, Cavallari A, Bianchi FB. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8: 10-20 [PMID: 11799480]
104. Grassi A, Quarneti C, Ravaioli M, Bianchini F, Susca M, D'Errico A, Piscaglia F, Tamè MR, Andreone P, Grazi G, Galli S, Zauli D, Pinna AD, Bianchi FB, Ballardini G. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl 2006; 12: 1673-1681 [PMID: 17031825]
105. Gruppioni E, Vasuri F, Fiorentino M, Capizzi E, Altimari A, Pirini MG, Grazi GL, Malvi D, Grigioni WF, D'Errico-Grigioni A. Real-time quantitative assay for routine testing of HCV RNA in formalin-fixed, paraffin-embedded liver samples. Diagn Mol Pathol 2009; 18: 232-238 [PMID: 19861893 DOI: 10.1097/PDM.0b013e3181916e31]
106. Nuovo GJ, Holly A, Wakely P, Frankel W. Correlation of histology, viral load, and in situ viral detection in hepatic biopsies from patients with liver transplants secondary to hepatitis C infection. Hum Pathol 2002; 33: 277-284 [PMID: 11979367]
107. Pessôa MG, Alves VA, Wakamatsu A, Gomes JG, Maertens G, van der Borght B, Kim M, Ferrell L, Wright TL. Post-transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications. Liver Int 2008; 28: 807-813 [PMID: 18422936 DOI: 10.1111/j.1478-3231.2008.01739.x]
108. Sadamori H, Yagi T, Iwagaki H, Matsuda H, Shinoura S, Umeda Y, Ohara N, Yanai H, Ogino T, Tanaka N. Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2009; 24: 574-580 [PMID: 19368635 DOI: 10.1111/j.1440-1746.2008.05638.x]
109. Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M, Gentili F, Onetti Muda A, Berloco P, Rossi M, Attili AF, Gaudio E. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis 2005; 37: 349-356 [PMID: 15843085]
110. Gawrieh S, Papouchado BG, Burgart LJ, Kobayashi S, Charlton MR, Gores GJ. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11: 1207-1213 [PMID: 16184568]
111. Russo MW, Firpi RJ, Nelson DR, Schoonhoven R, Shrestha R, Fried MW. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl 2005; 11: 1235-1241 [PMID: 16184580]
112. Carotti S, Morini S, Corradini SG, Burza MA, Molinaro A, Carpino G, Merli M, De Santis A, Muda AO, Rossi M, Attili AF, Gaudio E. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl 2008; 14: 806-814 [PMID: 18508359 DOI: 10.1002/lt.21436]
113. Zadori G, Gelley F, Torzsok P, Sárváry E, Doros A, Deak AP, Nagy P, Schaff Z, Kiss A, Nemes B. Examination of claudin-1 expression in patients undergoing liver transplantation owing to hepatitis C virus cirrhosis. Transplant Proc 2011; 43: 1267-1271 [PMID: 21620107 DOI: 10.1016/j.transproceed.2011.03.066]
114. Schmeding M, Dankof A, Krenn V, Krukemeyer MG, Koch M, Spinelli A, Langrehr JM, Neumann UP, Neuhaus P. C4d in acute rejection after liver transplantation--a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6: 523-530 [PMID: 16468961]
115. Lorho R, Turlin B, Aqodad N, Triki N, de Lajarte-Thirouard AS, Camus C, Lakehal M, Compagnon P, Dupont-Bierre E, Meunier B, Boudjema K, Messner M. C4d: a marker for hepatic transplant rejection. Transplant Proc 2006; 38: 2333-2334 [PMID: 16980082]
116. Jain A, Ryan C, Mohanka R, Orloff M, Abt P, Romano J, Bryan L, Batzold P, Mantry P, Bozorgzadeh A. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant 2006; 20: 624-633 [PMID: 16968489]
117. Fayek SA. The value of C4d deposit in post liver transplant liver biopsies. Transpl Immunol 2012; 27: 166-170 [PMID: 22975227 DOI: 10.1016/j.trim.2012.08.004]
118. MacQuillan GC, de Boer WB, Allan JE, Platten MA, Reed WD, Jeffrey GP. Hepatocellular MxA protein expression supports the differentiation of recurrent hepatitis C disease from acute cellular rejection after liver transplantation. Clin Transplant 2010; 24: 252-258 [PMID: 19712085 DOI: 10.1111/j.1399-0012.2009.01068.x]
119. Borgogna C, Toniutto P, Smirne C, Azzimonti B, Rittà M, Avellini C, Fabris C, Landolfo S, Gariglio M, Pirisi M. Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts. Histopathology 2009; 54: 837-846 [PMID: 19635103 DOI: 10.1111/j.1365-2559.2009.03311.x]
120. Marshall A, Rushbrook S, Morris LS, Scott IS, Vowler SL, Davies SE, Coleman N, Alexander G. Hepatocyte expression of minichromosome maintenance protein-2 predicts fibrosis progression after transplantation for chronic hepatitis C virus: a pilot study. Liver Transpl 2005; 11: 427-433 [PMID: 15776414]
121. Unitt E, Gelson W, Davies SE, Coleman N, Alexander GJ. Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009; 15: 306-312 [PMID: 19243005 DOI: 10.1002/lt.21680]
122. Di Martino V, Saurini F, Samuel D, Gigou M, Dussaix E, Reynès M, Bismuth H, Féray C. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997; 26: 1343-1350 [PMID: 9362382]
123. Fragulidis GP, Cirocco RE, Weppler D, Berho M, Gillian G, Markou M, Viciana A, Esquenazi V, Nery JR, Miller J, Reddy KR, Tzakis AG. In situ enzymatic oligonucleotide amplification of hepatitis C virus-RNA in liver biopsy specimens (reverse transcriptase in situ polymerase chain reaction) after orthotopic liver transplantation for hepatitis C-related liver disease. Transplantation 1998; 66: 1472-1476 [PMID: 9869088]
124. Aardema KL, Nakhleh RE, Terry LK, Burd EM, Ma CK, Moonka DK, Brown KA, Abouljoud MS. Quantitation of hepatitis C virus RNA in liver tissue of allografts: correlation with histologic features and liver function tests. Transplant Proc 1999; 31: 477-478 [PMID: 10083198]
125. Negro F, Giostra E, Krawczynski K, Quadri R, Rubbia-Brandt L, Mentha G, Colucci G, Perrin L, Hadengue A. Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. J Hepatol 1998; 29: 1-11 [PMID: 9696486]
126. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
127. Motomura T, Taketomi A, Fukuhara T, Mano Y, Takeishi K, Toshima T, Harada N, Uchiyama H, Yoshizumi T, Soejima Y, Shirabe K, Matsuura Y, Maehara Y. The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: significant lessons from a dual graft case. Am J Transplant 2011; 11: 1325-1329 [PMID: 21645259 DOI: 10.1111/j.1600-6143.2011.03537.x]
128. Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, Navasa M, Forns X. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-1057 [PMID: 21466653 DOI: 10.1111/j.1600-6143.2011.03491.x]
129. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289-298 [PMID: 21384511 DOI: 10.1002/lt.22235]
130. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324 [PMID: 21254179 DOI: 10.1002/hep.24074]
131. Duarte-Rojo A, Deneke MG, Charlton MR. Interleukin-28B polymorphism in hepatitis C and liver transplantation. Liver Transpl 2013; 19: 49-58 [PMID: 23008132 DOI: 10.1002/lt.23554]
132. Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2012; 27: 1467-1472 [PMID: 22432893 DOI: 10.1111/j.1440-1746.2012.07129.x]
133. Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, Mikuz G, Pratschke J, Margreiter R, Vogel W. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl 2012; 18: 671-679 [PMID: 22298465 DOI: 10.1002/lt.23402]
134. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Colletta C, Vandelli C, Cmet S, Ceriani E, Smirne C, Toniutto P, Pirisi M. The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Med Virol 2012; 84: 747-755 [PMID: 22431022 DOI: 10.1002/jmv.23259]
135. Dharancy S, Podevin P, Aoudjehane L, Batteux F, Rosenberg AR, Soubrane O, Calmus Y, Conti F. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. Transplantation 2007; 83: 906-911 [PMID: 17460561]
136. Gehrau R, Maluf D, Archer K, Stravitz R, Suh J, Le N, Mas V. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med 2011; 17: 824-833 [PMID: 21519635 DOI: 10.2119/molmed.2011.00072]